8-K: Neogen Reports Third-Quarter 2025 Results, Updates Full-Year Guidance

Neogen Corporation announces its third-quarter 2025 results, reporting revenue of $221.0 million and updating its full-year guidance due to lower-than-expected results and macroeconomic uncertainty.

Summary

• Neogen Corporation reported third-quarter 2025 revenue of $221.0 million, a 3.4% decrease compared to the prior year's $228.8 million.
• The company experienced a net loss of $11.0 million, or $(0.05) per diluted share, compared to a net loss of $2.0 million, or $(0.01) per diluted share, in the prior-year period.
• Adjusted Net Income was $20.9 million, or $0.10 per diluted share, compared to $26.4 million, or $0.12 per diluted share, in the prior-year period.
• Adjusted EBITDA was $48.5 million, with an Adjusted EBITDA Margin of 22.0%, compared to $52.7 million and a margin of 23.0% in the prior-year period.
• The Food Safety segment's revenue decreased by 3.2% to $152.7 million, while the Animal Safety segment's revenue decreased by 4.0% to $68.2 million.
• Neogen is updating its full-year outlook, now expecting revenue to be approximately $895 million and Adjusted EBITDA to be approximately $195 million.
• Capital expenditures are now expected to be approximately $100 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company highlights progress in certain areas, the overall results are below expectations, and the updated guidance reflects a more cautious outlook due to macroeconomic uncertainty.

Positives

• Core revenue in the Food Safety segment, excluding sample collection, grew by 7%.
• The company made significant improvements in sample collection production, reaching prior throughput levels by the end of the quarter.
• The establishment of Neogen's own Petrifilm production is progressing well, with initial test production expected in the fall.
• The biosecurity and bacterial & general sanitation product categories in the Food Safety segment benefited from strong growth in pathogen detection products.
• Growth in the Animal Safety segment was led by the animal care & other and biosecurity product categories.

Negatives

• Third-quarter results were lower than expected due to macroeconomic uncertainty and lower sample collection revenue.
• The company experienced a net loss of $11.0 million, a significant decrease compared to the prior year.
• Both domestic and international distributors were less willing to commit to inventory due to faltering consumer confidence and global trade concerns.
• The Genomics business experienced a core revenue decline in the mid-single-digit range.
• The company is updating its full-year outlook with lower expectations for revenue and Adjusted EBITDA.

Risks

• Macroeconomic uncertainty and global trade policies are impacting the company's end markets.
• Faltering consumer confidence and concerns about a potential recession are affecting distributor inventory commitments.
• The company faces risks associated with the integration of acquired businesses and the transition of manufacturing agreements.
• The company's performance is subject to fluctuations in foreign currency exchange rates.
• The company's forward-looking statements are subject to significant risks and uncertainties, as detailed in its SEC filings.

Future Outlook

Neogen is updating its full-year outlook, expecting revenue to be approximately $895 million and Adjusted EBITDA to be approximately $195 million. Capital expenditures are now expected to be approximately $100 million.

Management Comments

• During the third quarter, we continued to make good progress on the integration and saw a solid underlying performance in our Food Safety segment, said John Adent, Neogen's President and Chief Executive Officer.
• We remain optimistic about the future trajectory of the business and believe the changes we are making will allow us to not only manage through the current uncertainty, but also position us to deliver on the long-term growth opportunity in front of us.

Industry Context

Neogen operates in the food safety and animal safety industries, which are generally considered relatively insulated against economic downturns. However, the company is facing challenges related to macroeconomic uncertainty and global trade policies, which are impacting distributor inventory commitments. The company's focus on integration and improved execution is aimed at navigating these challenges and positioning the company for long-term growth.

Comparison to Industry Standards

• It's difficult to provide a precise comparison to industry standards without knowing Neogen's specific product mix and geographic focus.
• However, companies like Thermo Fisher Scientific, Danaher Corporation (specifically their food safety divisions), and Zoetis (in the animal health sector) are often considered benchmarks.
• Neogen's adjusted EBITDA margin of 22.0% is a key metric to compare against these peers, as is their revenue growth (or decline) in core segments.
• The impact of the 3M integration is a unique factor for Neogen, and the success of this integration will be crucial for future performance relative to its competitors.

Stakeholder Impact

• Shareholders will be impacted by the lower-than-expected results and updated guidance.
• Employees may be affected by restructuring activities and transformation initiatives.
• Customers may experience changes in product availability or pricing due to integration and supply chain adjustments.
• Suppliers may be impacted by changes in procurement strategies as a result of the integration.
• Creditors will be monitoring the company's financial performance and ability to meet its debt obligations.

Next Steps

• Neogen will host a conference call to discuss the financial results.
• The company will continue to focus on integration and improved execution to navigate current uncertainties and position itself for long-term growth.
• The company expects to begin initial test production of Petrifilm in the fall.

Key Dates

Keywords

Neogen, Financial Results, Third Quarter, Food Safety, Animal Safety, Revenue, EBITDA, Net Loss, Guidance, Petrifilm